Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000152243 | SCV000201050 | uncertain significance | not specified | 2014-05-09 | criteria provided, single submitter | clinical testing | The Arg19914Gln variant in TTN has not been previously reported in individuals w ith cardiomyopathy, but has been identified in 2/3800 African American chromosom es by the NHLBI Exome Sequencing Project (http://evs.gs.washington.edu/EVS/; dbS NP rs200146608). Computational prediction tools and conservation analysis do not provide strong support for or against an impact to the protein. In summary, the clinical significance of the Arg19914Gln variant is uncertain. |
Gene |
RCV001704098 | SCV000237456 | likely benign | not provided | 2020-06-17 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000552973 | SCV000643562 | uncertain significance | Dilated cardiomyopathy 1G; Autosomal recessive limb-girdle muscular dystrophy type 2J | 2017-05-29 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002354350 | SCV002622345 | uncertain significance | Cardiovascular phenotype | 2019-11-01 | criteria provided, single submitter | clinical testing | The p.R13417Q variant (also known as c.40250G>A), located in coding exon 146 of the TTN gene, results from a G to A substitution at nucleotide position 40250. The arginine at codon 13417 is replaced by glutamine, an amino acid with highly similar properties. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV001704098 | SCV003820202 | uncertain significance | not provided | 2021-12-19 | criteria provided, single submitter | clinical testing |